Lung cancer remains the world’s most commonly diagnosed cancer and its leading cause of cancer-related mortality. Although declining smoking rates have reduced incidence among men in many countries, lung cancer is increasing among younger women who have never smoked. Non-small cell lung cancer accounts for most cases and is frequently associated with genetic alterations that continuously stimulate cellular growth. Mutations in the epidermal growth factor receptor, or EGFR, can keep growth-promoting signals switched on, while alterations in KRAS can disrupt a central molecular relay that transmits those signals inside the cell. Targeted inhibitors directed against these pathways have transformed treatment for many patients, yet resistance commonly emerges as tumours adapt, acquire additional mutations or activate alternative survival mechanisms.

The new approach focuses on HER3, a member of the epidermal growth factor receptor family that is present on the surface of most non-small cell lung cancers. HER3-DXd is an antibody-drug conjugate designed to exploit this molecular feature. Its antibody component binds to HER3 on cancer cells and is taken into the cell, where the attached drug is released. The payload belongs to the topoisomerase I inhibitor class and interferes with the process by which DNA is unwound and copied. This creates DNA lesions that can become particularly toxic when a cancer cell is dividing. Because HER3 is broadly expressed across genetically different lung tumours, the strategy may be less dependent on a single oncogenic mutation than conventional targeted therapies.

Olaparib attacks a different vulnerability. It inhibits PARP proteins, which help detect and repair certain forms of DNA damage, including single-strand breaks. When PARP activity is blocked, these lesions can persist and become more dangerous during DNA replication, eventually developing into double-strand breaks. Healthy cells often possess several overlapping repair systems, but tumour cells may already be operating under considerable genomic stress or may carry defects in DNA-repair pathways. Combining olaparib with HER3-DXd therefore creates a form of therapeutic pressure in which the antibody-drug conjugate generates extensive damage while the PARP inhibitor prevents the cancer cell from resolving it. The result is an accumulation of irreparable lesions and activation of programmed cell death, or apoptosis.

Experiments described in the study showed that the combination was significantly more effective than either HER3-DXd or olaparib used separately. The researchers observed increased markers of DNA damage and a greater loss of cancer-cell viability in models of non-small cell lung cancer. Importantly, the effect was detected in models carrying both EGFR and KRAS mutations, two genetically distinct settings that often respond differently to treatment. This broad activity suggests that the combination may work through a biological vulnerability shared by many lung cancers rather than relying exclusively on the presence of one particular driver mutation. The findings also raise the possibility that tumours that have become resistant to standard EGFR-directed therapies could remain susceptible to a treatment based on HER3 expression and DNA-repair disruption.

The researchers tested the therapy in more complex experimental systems as well as in cultured cells. A cancer-on-a-chip model constructed from a patient’s own cancer cells reproduced features of a tumour together with its surrounding vasculature, allowing the investigators to examine treatment responses under laboratory conditions that more closely resemble human disease. Such models can capture interactions between tumour cells, blood-vessel-like structures and therapeutic agents that are difficult to reproduce in conventional two-dimensional cultures. In animal studies, the combined treatment slowed tumour growth and extended survival compared with single-agent therapy. These results strengthen the evidence that the interaction between HER3-DXd and olaparib is not limited to an artificial laboratory setting.

The treatment also appeared to stimulate an immune response against the tumour. One important mechanism involved the cGAS-STING pathway, a surveillance system that detects abnormal DNA in the cell. When damaged or misplaced DNA accumulates in the cytoplasm, the enzyme cGAS can generate cyclic GMP-AMP, which activates the adaptor protein STING. This signalling cascade induces inflammatory mediators and interferon-related responses that alert the innate immune system to cellular danger. By increasing DNA damage, the drug combination may therefore make tumour cells more visible to immune defences. In the study, this response was accompanied by improved activity of natural killer cells, immune cells that can recognise and destroy stressed or abnormal cells without requiring the same antigen-specific priming as conventional T-cell responses.

This dual action is significant because successful cancer therapy often depends on more than direct tumour-cell killing. A treatment that damages cancer cells but leaves behind a microenvironment capable of suppressing immunity may produce only a temporary response. By contrast, the HER3-DXd and olaparib combination appears to link intracellular DNA damage with external immune activation. The damaged tumour may release signals that encourage inflammation, while natural killer cells gain a greater capacity to attack malignant targets. Whether this immune effect will be equally strong in patients remains unknown, since human tumours contain diverse immune populations and often develop mechanisms that block immune surveillance. Nevertheless, the preclinical observations provide a mechanistic basis for investigating the combination alongside other immunomodulatory strategies.

The researchers suggest that HER3 itself could eventually serve as a biomarker for selecting patients most likely to benefit. Unlike a mutation-specific marker, HER3 expression could identify a wider group of patients whose tumours possess the molecular entry point required for HER3-DXd. However, expression alone may not fully predict response. The amount of HER3 on the cell surface, the efficiency with which the antibody-drug conjugate is internalised, the condition of the tumour’s DNA-repair machinery and the composition of the immune microenvironment could all influence treatment outcomes. Clinical studies will need to determine the appropriate doses, establish whether the combination produces manageable levels of toxicity and clarify how HER3 abundance, EGFR or KRAS status and previous treatment history affect response.

The study’s findings may have implications beyond lung cancer. HER3 is frequently detected in other solid tumours, including several cancers in which resistance to targeted therapy remains a major clinical challenge. If the same relationship between HER3-directed drug delivery, PARP inhibition and immune activation is observed in patients, the strategy could potentially be adapted to additional tumour types. At present, however, the evidence remains preclinical, and results from cell cultures, organ-like models and laboratory animals cannot guarantee benefit in humans. The work provides a strong foundation for clinical testing, but future trials will be essential to determine whether this precisely engineered combination can translate its promise into longer, more durable responses for people with treatment-resistant cancer.

Subject of Research: A preclinical combination therapy using HER3-DXd and olaparib to treat non-small cell lung cancer.

Article Title: PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer

News Publication Date: 21-Aug-2026

Web References: https://doi.org/10.1016/j.xcrm.2026.103002

References: Cell Reports Medicine, DOI: 10.1016/j.xcrm.2026.103002

Image Credits: Linh Lin and Bassel Alsaed

Keywords: Lung cancer, non-small cell lung cancer, HER3-DXd, patritumab deruxtecan, olaparib, PARP inhibition, DNA damage, EGFR, KRAS, cGAS-STING, natural killer cells, cancer immunology, targeted therapy, drug resistance, cancer-on-a-chip model

Recent groundbreaking research suggests a compelling answer lies in the strategic inhibition of ATR (ataxia telangiectasia and Rad3-related protein), a critical kinase orchestrating the cellular DNA damage response (DDR). The DDR is essential for maintaining genomic integrity, particularly under stress conditions such as those induced by cancer therapies. ATR functions as a guardian of genome stability, triggering cell cycle arrest and activating DNA repair pathways in response to replication stress and DNA damage. Recognizing this, researchers hypothesized that pharmacological blockade of ATR could potentiate the antitumor cytotoxicity of HER3-DXd by amplifying DNA damage and curtailing repair mechanisms in HER3-positive/HR-positive breast cancer cells, including models resistant to tamoxifen, a commonly used endocrine therapy.

This hypothesis stems from a mechanistic insight into how cancer cells evade therapy-induced cell death. HER3-DXd operates by delivering cytotoxic payloads directly to HER3-overexpressing cancer cells, causing DNA damage that ideally culminates in apoptosis. However, the cancer cells’ intrinsic DDR machinery often mitigates this assault by repairing DNA lesions, contributing to therapeutic resistance. By interrupting ATR signaling, these repair pathways can be dismantled, potentially overwhelming the tumor cells with unrepaired DNA damage and pushing them toward irreversible cell death.

Experimental validation of this approach was conducted using preclinical models representative of HR+ breast cancer, with a focus on tamoxifen-resistant phenotypes. The researchers demonstrated that combining HER3-DXd with ATR inhibitors significantly increased DNA damage markers within tumor cells compared to either treatment alone. These findings indicate a synergistic interaction whereby ATR inhibition amplifies the genotoxic stress induced by HER3-DXd. Consequent analyses revealed heightened levels of DNA double-strand breaks and replication stress, hallmarks of effective anticancer treatment infliction.

Functional assays further confirmed that the dual treatment severely impaired tumor cell viability and clonogenic potential. Importantly, this effect was markedly pronounced in tamoxifen-resistant cell lines, suggesting that ATR inhibition could sensitize tumors that have developed resistance to standard endocrine therapies. This revelation offers a promising avenue for overcoming one of the most vexing therapeutic hurdles in HR+ breast cancer management.

The translational significance of this work cannot be overstated. Despite the clinical promise of HER3-DXd, its efficacy may be limited by the robust DNA repair capabilities in cancer cells. Dual targeting with ATR inhibitors logically extends the therapeutic window, creating a synthetic lethal milieu in which tumor cells succumb due to their inability to rectify lethal DNA damage. Such combination strategies could redefine treatment paradigms, particularly for patients whose tumors have ceased responding to endocrine agents such as tamoxifen.

Beyond cellular assays, in vivo models corroborated enhanced tumor growth suppression with the combined regimen, reinforcing the therapeutic potential and setting the stage for clinical investigation. These preclinical insights advocate for clinical trials that incorporate ATR inhibitors with HER3-targeted antibody-drug conjugates, which could revolutionize the therapeutic landscape for HER3-positive and endocrine-resistant breast cancer cohorts.

From a molecular perspective, this study elucidates how DNA repair pathways interplay with receptor tyrosine kinase signaling and therapeutic susceptibility. By intricately dissecting these relationships, the research contributes vital knowledge to the cancer biology field, highlighting how the vulnerabilities of DNA damage repair can be exploited in conjunction with targeted delivery of cytotoxic agents.

The implications of ATR inhibition extend beyond breast cancer. Given the ubiquity of DNA repair mechanisms in diverse tumor types, the principles unveiled here may catalyze broader oncology applications. Combination therapies that thwart adaptive repair responses while simultaneously administering targeted cytotoxins could become a versatile strategy against various malignancies harboring similar resistance profiles.

While the promise is significant, challenges remain. The potential toxicity of ATR inhibitors, particularly in combination regimens, requires careful evaluation. The balance between maximizing tumor cell kill and minimizing harm to normal proliferating cells forms an intricate therapeutic tightrope. Ongoing research must address optimal dosing, scheduling, and biomarker development to identify patients most likely to benefit from this approach.

Moreover, the heterogeneity of HER3 expression within tumors and the dynamic evolution of resistance mechanisms call for personalized medicine strategies. Integrating genomic and proteomic analyses may enable precise stratification and monitoring, ensuring that patients receive tailored interventions, enhancing efficacy while curbing adverse effects.

In conclusion, targeting the ATR-mediated DNA damage response pathway represents a compelling advancement in the fight against HER3-positive, hormone receptor–positive breast cancer, particularly in the challenging context of endocrine resistance. The synergism observed with HER3-DXd posits a novel combinational therapy that undermines cancer cells’ repair defenses, accentuating DNA damage and fostering robust antitumor effects. These findings, published in the British Journal of Cancer, open new horizons for translational research and clinical innovation, fueling hope for improved outcomes in metastatic breast cancer patients who currently face limited options.

As with all pioneering treatments, further clinical validation is essential to confirm safety, efficacy, and long-term benefits. Nonetheless, the strategic blockade of ATR to enhance HER3-directed therapeutics may soon herald a new era, promising to surmount one of the most persistent barriers in breast cancer treatment and offering renewed optimism for countless patients worldwide.

Subject of Research:
Targeting ATR to enhance the efficacy of HER3-DXd in hormone receptor–positive, HER3-expressing breast cancer, particularly addressing endocrine therapy resistance.

Article Title:
ATR inhibition potentiates the antitumor efficacy of HER3-DXd in HER3-positive/HR-positive breast cancer by increasing DNA damage.

Article References:
Xie, X., Lee, J., Gi, Y.J. et al. ATR inhibition potentiates the antitumor efficacy of HER3-DXd in HER3-positive/HR-positive breast cancer by increasing DNA damage. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03413-1

Image Credits:
AI Generated

DOI:
15 April 2026